Pla, Helena
Felip, Eudald
Obadia, Verónica
Pernas, Sonia
Viñas, Gemma
Margelí, Mireia
Fort-Culillas, Roser
Del Barco, Sonia
Sabaté, Nuria
Fort, Eduard
Lezcano, Clara
Cirauqui, Beatriz
Quiroga, Vanesa
Stradella, Agostina
Gil Gil, Miguel
Esteve, Anna
Recalde, Sabela http://orcid.org/0009-0005-4385-4115
Article History
Received: 17 October 2023
Accepted: 24 January 2024
First Online: 22 March 2024
Declarations
:
: E. Felip reports honoraria received from Novartis as advisory role and travel expenses from Novartis, Pfizer and Lilly. H. Pla reports honoraria received from Pfizer as advisory role and travel expenses from Novartis, Pfizer, and Lilly. V. Quiroga reports honoraria received from Novartis and Roche as advisory role or speaker and travel or inscription expenses from GSK, Lilly, and Roche. M. Margelí reports honoraria received from Novartis, Pfizer, Lilly, Gilead, Piere Fabre, and MSD as advisory role or consulting, research funding from Pfizer and travel expenses from Pfizer and Gilead. B. Cirauqui reports honoraria received from BMS, MSD, and Merck as invited speaker; and training grants from BMS and MSD. A. Stradella reports honoraria received from Daiichi Sankyo and Novartis as invited speaker, from Eisai, Novartis, and Pfizer for travel or inscription expenses and from Astra Zeneca, Boehringer Ingelheim, Novartis, Seagen, and Gilead as advisory role. S. Recalde reports honoraria from Gilead, Novartis, and Roche as invited speaker and from Astra Zeneca, Novartis, and Accord for travel or inscription expenses. M. Gil reports honoraria received from Pfizer, Novartis, and Astra Zeneca. From Lilly, Daiichi Sankyo, and Pfizer for travel and inscription expenses and from Astra Zeneca, Seagen, and Gilead for advisory role. G. Viñas reports honoraria received from Roche, Pfizer, AstraZeneca, Daiichi Sankyo, Accord, Eisai, and Novartis as speaker, grant support from Novartis, and travel expenses from Roche, Pfizer, AstraZeneca, Daiichi Sankyo, and Novartis.